Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Protein Design Labs, Inc. (NasdaqNM:PDLI)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Reports
Location
34801 Campus Drive
Fremont, CA 94555
Phone: (510) 574-1400
Email: cc@pdl.com
Employees (last reported count): 307
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Index Membership
 ·S&P 400 MidCap
Ownership
·Insider and 5%+ Owners: 19%
·Over the last 6 months:
 · one insider sell; 2,000  shares
·Institutional: 79% (98% of float)
(492 institutions)
·Net Inst. Buying: 2.97M shares (+7.86%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Protein Design Labs, Inc is engaged in the development of humanized monoclonal antibodies for the prevention and treatment of disease. The Company has licensed certain rights to its first humanized antibody product, Zenapax, to Hoffmann-La Roche Inc. and its affiliates (Roche), which markets Zenapax for the prevention of kidney transplant rejection. The Company is also testing Zenapax for the treatment of autoimmune disease. In addition, the Company has several other humanized antibodies in clinical development for autoimmune and inflammatory conditions, asthma and cancer. The Company has fundamental patents in the United States, Europe and Japan, that cover many humanized antibodies. Eleven companies have licenses under these patents for humanized antibodies that they have developed. The Company receives royalties on sales of the three humanized antibodies developed by other companies that are currently being marketed.
More from Market Guide: Expanded Business Description

Financial Summary
PDLI develops human and humanized antibodies and other potential drugs to prevent or treat certain disease conditions, including viral infections, autoimmune diseases and certain cancers. For the six months ended 6/30/01, revenues increased 33% to $47.8 million. Net income increased 69% to $9.8 million. Revenues reflect increased interest income. Earnings also reflect decreased research and development expenses as a percentage of revenues.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Laurence Korn, Ph.D., 51
CEO and Chairman
$446K$19.9M
Cary Queen, Ph.D., 50
Sr. VP, VP, Research
316K11.7M
Douglas Ebersole, 54
Sr. VP, Licensing and Corp. Services, Sec.
366K5.2M
Daniel Levitt, M.D., Ph.D., 54
Sr. VP of Clinical and Regulatory Affairs
389K6.9M
Sergio Garcia-Rodriguez
VP, Legal, Gen. Counsel and Assistant Sec.
--  --  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:PDLIAs of 31-Aug-2001
Price and Volume
52-Week Low
on 22-Mar-2001
$32.50 
Recent Price$58.79 
52-Week High
on 3-Nov-2000
$146.25 
Beta-0.02 
Daily Volume (3-month avg)1.89M
Daily Volume (10-day avg)2.02M
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-26.9%
52-Week Change
relative to S&P500
-1.9%
Share-Related Items
Market Capitalization$2.58B
Shares Outstanding43.8M
Float35.5M
Dividends & Splits
Annual Dividendnone 
Last Split: 2 for 1 on 23-Aug-2000
Per-Share Data
Book Value (mrq)$12.63 
Earnings (ttm)$0.08 
Earnings (mrq)$0.07 
Sales (ttm)$1.70 
Cash (mrq)$14.73 
Valuation Ratios
Price/Book (mrq)4.66 
Price/Earnings (ttm)716.95 
Price/Sales (ttm)34.53 
Income Statements
Sales (ttm)$75.0M
EBITDA (ttm)$18.5M
Income available to common (ttm)$4.63M
Profitability
Profit Margin (ttm)6.2%
Operating Margin (ttm)6.2%
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)0.72%
Return on Equity (ttm)0.99%
Financial Strength
Current Ratio (mrq)65.32 
Debt/Equity (mrq)0.29 
Total Cash (mrq)$645.8M
Short Interest
As of 8-Aug-2001
Shares Short3.55M
Percent of Float10.0%
Shares Short
(Prior Month)
2.86M
Short Ratio1.99 
Daily Volume1.78M
See Profile Help for a description of each item above;   M = millions;   B = billions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.